Literature DB >> 24859000

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

N G L Jager1, H Rosing, J H M Schellens, J H Beijnen, S C Linn.   

Abstract

The anti-estrogenic effect of tamoxifen is suggested to be mainly attributable to its metabolite (Z)-endoxifen, and a minimum therapeutic threshold for (Z)-endoxifen in serum has been proposed. The objective of this research was to establish the relationship between dried blood spot (DBS) and serum concentrations of tamoxifen and (Z)-endoxifen to allow the use of DBS sampling, a simple and patient-friendly alternative to venous sampling, in clinical practice. Paired DBS and serum samples were obtained from 50 patients using tamoxifen and analyzed using HPLC-MS/MS. Serum concentrations were calculated from DBS concentrations using the formula calculated serum concentration = DBS concentration/([1-haematocrit (Hct)] + blood cell-to-serum ratio × Hct). The blood cell-to-serum ratio was determined ex vivo by incubating a batch of whole blood spiked with both analytes. The average Hct for female adults was imputed as a fixed value. Calculated and analyzed serum concentrations were compared using weighted Deming regression. Weighted Deming regression analysis comparing 44 matching pairs of DBS and serum samples showed a proportional bias for both analytes. Serum concentrations were calculated using [Tamoxifen] serum, calculated  = [Tamoxifen] DBS /0.779 and [(Z)-Endoxifen] serum, calculated = [(Z)-Endoxifen] DBS /0.663. Calculated serum concentrations were within 20 % of analyzed serum concentrations in 84 and 100 % of patient samples for tamoxifen and (Z)-endoxifen, respectively. In conclusion, DBS concentrations of tamoxifen and (Z)-endoxifen were equal to serum concentrations after correction for Hct and blood cell-to-serum ratio. DBS sampling can be used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24859000     DOI: 10.1007/s10549-014-2999-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

Review 1.  Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: a Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations.

Authors:  Valentina Iacuzzi; Bianca Posocco; Martina Zanchetta; Sara Gagno; Ariana Soledad Poetto; Michela Guardascione; Giuseppe Toffoli
Journal:  Pharm Res       Date:  2021-04-12       Impact factor: 4.200

2.  Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.

Authors:  Urs Duthaler; Claudia Suenderhauf; Mats O Karlsson; Janine Hussner; Henriette Meyer Zu Schwabedissen; Stephan Krähenbühl; Felix Hammann
Journal:  Br J Clin Pharmacol       Date:  2019-01-24       Impact factor: 4.335

3.  Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients.

Authors:  Baitha Palanggatan Maggadani; Samuel J Haryono; Marcellino Ryan Rinaldi; Yahdiana Harahap
Journal:  Drug Des Devel Ther       Date:  2021-06-04       Impact factor: 4.162

4.  Analysis of tamoxifen and its metabolites in dried blood spot and volumetric absorptive microsampling: comparison and clinical application.

Authors:  Baitha Palanggatan Maggadani; Yahdiana Harahap; Samuel J Haryono; Christoffel William Putra Untu
Journal:  Heliyon       Date:  2021-06-10

5.  Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.

Authors:  M van Nuland; R A Vreman; R M T Ten Ham; A H M de Vries Schultink; H Rosing; J H M Schellens; J H Beijnen; A M Hövels
Journal:  Breast Cancer Res Treat       Date:  2018-07-13       Impact factor: 4.872

6.  Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer.

Authors:  Stefan Rehnmark; Ivan Shabo; Håkan Randahl; Yvonne Wengström; Per Rydberg; Elham Hedayati
Journal:  Sci Rep       Date:  2022-01-31       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.